Page 90 - Read Online

Page 454 Michaelis et al. Cancer Drug Resist 2019;2:447-56 I http://dx.doi.org/10.20517/cdr.2019.005

35. Dai X, Cheng H, Bai Z, Li J. Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping. J Cancer
2017;8:3131-41.
36. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23.
37. Goodspeed A, Heiser LM, Gray JW, Costello JC. Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics. Mol
Cancer Res 2016;14:3-13.
38. Geraghty RJ, Capes-Davis A, Davis JM, Downward J, Freshney RI, et al. Guidelines for the use of cell lines in biomedical research. Br J
Cancer 2014;111:1021-46.
39. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, et al. The Cancer Cell Line Encyclopedia enables predictive
modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
40. Basu A, Bodycombe NE, Cheah JH, Price EV, Liu K, et al. An interactive resource to identify cancer genetic and lineage dependencies
targeted by small molecules. Cell 2013;154:1151-61.
41. Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for
therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 2013;41:D955-61.
42. Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, et al. A Landscape of Pharmacogenomic Interactions in Cancer. Cell
2016;166:740-54.
43. Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, et al. Next-generation characterization of the Cancer Cell Line
Encyclopedia. Nature 2019; 569:503-8.
44. Petljak M, Alexandrov LB, Brammeld JS, Price S, Wedge DC, et al. Characterizing Mutational Signatures in Human Cancer Cell Lines
Reveals Episodic APOBEC Mutagenesis. Cell 2019;176:1282-94.e20.
45. van der Meer D, Barthorpe S, Yang W, Lightfoot H, Hall C, et al. Cell Model Passports-a hub for clinical, genetic and functional datasets
of preclinical cancer models. Nucleic Acids Res 2019;47:D923-29.
46. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta
1976;455:152-62.
47. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov
2006;5:219-34.
48. Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat
Rev Cancer 2018;18:452-64.
49. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, et al. Overexpression of a transporter gene in a multidrug-resistant human lung
cancer cell line. Science 1992;258:1650-4.
50. Roskoski R Jr. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res
2018;139:395-411.
51. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. MET amplification leads to gefitinib resistance in lung cancer by
activating ERBB3 signaling. Science 2007;316:1039-43.
52. Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, et al. Tumor cells can follow distinct evolutionary paths to
become resistant to epidermal growth factor receptor inhibition. Nat Med 2016;22:262-9.
53. Ramirez M, Rajaram S, Steininger RJ, Osipchuk D, Roth MA, et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant
cancer persister cells. Nat Commun 2016;7:10690.
54. Torres-Collado AX, Knott J, Jazirehi AR. Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from
Vemurafenib (BRAFV600E-Specific Inhibitor). Cancers (Basel) 2018;10:E157.
55. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS
upregulation. Nature 2010;468:973-7.
56. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly
spliced BRAF(V600E). Nature 2011;480:387-90.
57. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Ket al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-
mediated acquired B-RAF inhibitor resistance. Nat Commun 2012;3:724.
58. Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, et al. FAS and NF-κB signalling modulate dependence of lung cancers
on mutant EGFR. Nature 2011;471:523-6.
59. Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, et al. Patient-derived models of acquired resistance can identify effective
drug combinations for cancer. Science 2014;346:1480-6.
60. Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, et al. A clinically relevant androgen receptor mutation confers resistance to second-
generation antiandrogens enzalutamide and ARN-509. Cancer Discov 2013;3:1020-9.
61. Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, et al. An F876L mutation in androgen receptor confers genetic and phenotypic
resistance to MDV3100 (enzalutamide). Cancer Discov 2013;3:1030-43.
62. Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013;13:83-96.
63. Cinatl J Jr, Speidel D, Hardcastle I, Michaelis M. Resistance acquisition to MDM2 inhibitors. Biochem Soc Trans 2014;42:752-7.
64. Tisato V, Voltan R, Gonelli A, Secchiero P, Zauli G. MDM2/X inhibitors under clinical evaluation: perspectives for the management of
hematological malignancies and pediatric cancer. J Hematol Oncol 2017;10:133.
65. Aziz MH, Shen H Maki CG. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene
2011;30:4678-86.
66. Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, et al. Adaptation of cancer cells from different entities to the MDM2